Drugs / AuriNovo
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04399239 | Aug 2021 → May 2023 | microtia | 3DBio Therapeutics | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AuriNovo | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04399239 ↗ |
| Modality | Other / unclassified | “The construct is a 3D-bioprinted collagen hydrogel scaffold encapsulating the patient's own auricular cartilage cells (chondrocytes).” NCT04399239 ↗ |
| Route | Other | “The construct is printed in a size and shape that matches the contralateral ear for implantation into the patient.” NCT04399239 ↗ |